Glioblastoma multiforme (GBM) is
the deadliest brain cancer. The National Foundation for Cancer Research (NFCR) congratulated Dr. Web Cavenee and Dr. Paul B. Fisher on their discovery
of a new pharmacological agent to treat glioblastoma multiforme which they have been developing together
with NFCR support.
This new pharmacological agent could - with additional chemistry - lead to a new drug to prevent radiation-induced invasion of GBM cells. The researchers have tested their pharmacological agent in combination with radiation with profound survival benefits in pre-clinical models.
Paul B. Fisher, Director of the Virginia Commonwealth University's (VCU) Institute of Molecular Medicine (VIMM), focuses on cancer genetics and Web Cavenee, Director of the Ludwig Institute for Cancer Research at the University of California at San Diego focuses on GBM.
NFCR has been funding Dr. Fisher's research since 2008, and Dr. Cavenee's research starting in 2002.
"NFCR scientists are making headway in the fight against one of the most aggressive form of cancer, GBM, by working together on vital pre-clinical models," said Franklin C. Salisbury, Jr., NFCR CEO. "For years, discoveries from NFCR-funded research have led to better treatments today - and this latest discovery by two incredibly talented scientists gives us proof there will be improved therapies for GBM and multiple cancers in the foreseeable future."